Patents by Inventor Kelly Banducci

Kelly Banducci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alpha-synuclein kinase
    Patent number: 8148089
    Abstract: The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: April 3, 2012
    Assignee: Elan Pharma International Limited
    Inventors: John P. Anderson, Kelly Banducci, Guriqbal S. Basi, David Chereau, Tamie J. Chilcote, Normand L. Frigon, Jr., Jason Goldstein, Irene Griswold
  • ALPHA-SYNUCLEIN KINASE
    Publication number: 20110207796
    Abstract: Agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient are provided. Preferred agents include inhibitors of PLK2 kinase.
    Type: Application
    Filed: February 13, 2009
    Publication date: August 25, 2011
    Inventors: John P. Anderson, Kelly Banducci, Guriqbal S. Basi, David Chereau, Tamie J. Chilcote, Normand L. Frigon, JR., Jason Goldstein, Irene Griswold-Prenner
  • ALPHA-SYNUCLEIN KINASE
    Publication number: 20100143946
    Abstract: The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase.
    Type: Application
    Filed: February 8, 2010
    Publication date: June 10, 2010
    Applicant: ELAN PHARMA INTERNATIONAL LIMITED
    Inventors: JOHN P. ANDERSON, KELLY BANDUCCI, GURIQBAL S. BASI, DAVID CHEREAU, TAMIE J. CHILCOTE, NORMAND L. FRIGON, JR., JASON GOLDSTEIN, IRENE GRISWOLD-PRENNER
  • Alpha-synuclein kinase
    Patent number: 7553639
    Abstract: The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 and GRK6 kinases.
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: June 30, 2009
    Assignee: Elan Pharma International Limited
    Inventors: Tami J. Chilcote, Kelly Banducci, Normand L. Frigon, Jr., Guriqbal S. Basi, John P. Anderson, Jason Goldstein, Irene Griswold-Prenner, David Chereau
  • Alpha-Synuclein Kinase
    Publication number: 20080300206
    Abstract: The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase.
    Type: Application
    Filed: February 13, 2008
    Publication date: December 4, 2008
    Applicant: ELAN PHARMACEUTICALS, INC.
    Inventors: John P. Anderson, Kelly Banducci, Guriqbal S. Basi, David Chereau, Tamie J. Chilcote, Normand L. Frigon, JR., Jason Goldstein, Irene Griswold-Prenner
  • ALPHA-SYNUCLEIN KINASE
    Publication number: 20080160011
    Abstract: The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 and GRK6 kinases.
    Type: Application
    Filed: January 30, 2007
    Publication date: July 3, 2008
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: Tami J. Chilcote, Kelly Banducci, Normand L. Frigon, Guriqbal S. Basi, John P. Anderson, Jason Goldstein, Irene Griswold-Prenner, David Chereau